Document is current
Any future updates will be listed below
-
Authors
Bieber, Thomas
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 22 April 2025
First Online: 19 August 2025
Conflict of interest
: T. Bieber was speaker and/or consultant and/or investigator for AbbVie, Affibody, Almirall, Amagma/Triveni, AnaptysBio, AOBiom, Anergis, Apogee, Arena, Aristea, Artax, Asana Biosciences, ASLAN pharma, Astria, Attovia, BambusTx, Bayer Health, Belenos, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, BYOME Labs, Cantargia, CellDex, Connect Pharma, Daichi-Sanyko, Dermavant, DICE Therapeutics, DirigentBio, Domain Therapeutics, DS Pharma, EQRx, EMD Serono, Galderma, Galapagos, Gilead, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L’Oréal, Mabylon, MSD, Medac, Micreos, Nektar, Nextech, Novartis, Numab, OM-Pharma, Ornavi, Overtone, Pfizer, Pierre Fabre, Protagonist Tx, Q32bio, RAPT, Samsung Bioepis, Sanofi/Regeneron, Scienta Lab, TIRmed, UCB, Union Therapeutics, UPStream Bio, YUHAN. He is founder and chairman of the board of the nonprofit biotech Davos Biosciences AG within the international Kühne-Foundation and founder of the consulting firm Bieber Dermatology Consulting.
